HighTower Advisors
NDRM

HighTower Advisors’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

HighTower Advisors’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,550
Closed -$226K – 2435
2017
Q2 		$226K Sell
7,550
-1,600
-17% -$41.4K ﹤0.01% 1789
2017
Q1 		$242K Buy
+9,150
New +$227K ﹤0.01% 1668
2016
Q2 		– Sell
-12,150
Closed -$171K – 2178
2016
Q1 		$171K Hold
12,150
– – ﹤0.01% 1835
2015
Q4 		$207K Sell
12,150
-850
-7% -$16.6K ﹤0.01% 1733
2015
Q3 		$269K Buy
13,000
+3,000
+30% +$61.5K ﹤0.01% 1503
2015
Q2 		$154K Buy
+10,000
New +$141K ﹤0.01% 1389

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

HighTower Advisors's NDRM Position: Q3 2017 in Review

HighTower Advisors sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 7,550 shares — an estimated $226K sold.

HighTower Advisors first reported a position in NDRM in Q2 2015 and held it in 6 quarters. The position peaked at $269K in Q3 2015. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • HighTower Advisors reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • HighTower Advisors sold 7,550 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $226K.
  • HighTower Advisors first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2015 and held it in 6 quarters.
  • HighTower Advisors's NeuroDerm Ltd. Ordinary Shares position peaked at $269K in Q3 2015.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on HighTower Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.